Last reviewed · How we verify
Naloxone infusion
Naloxone is an opioid antagonist that blocks opioid receptors to reverse opioid overdose and respiratory depression.
Naloxone is an opioid antagonist that blocks opioid receptors to reverse opioid overdose and respiratory depression. Used for Opioid overdose reversal, Opioid-induced respiratory depression.
At a glance
| Generic name | Naloxone infusion |
|---|---|
| Sponsor | Middle Tennessee Research Institute |
| Drug class | Opioid antagonist |
| Target | Opioid receptors (mu, delta, kappa) |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine / Toxicology |
| Phase | FDA-approved |
Mechanism of action
Naloxone competitively binds to opioid receptors (mu, delta, and kappa) with higher affinity than opioids, displacing opioids from these receptors and rapidly reversing their effects. This mechanism restores normal respiratory function and consciousness in opioid overdose. The infusion formulation allows for sustained reversal of long-acting opioids and prevention of re-sedation.
Approved indications
- Opioid overdose reversal
- Opioid-induced respiratory depression
Common side effects
- Acute withdrawal syndrome
- Hypertension
- Tachycardia
- Diaphoresis
- Agitation
Key clinical trials
- Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank (PHASE1)
- Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI (PHASE2)
- Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers. (PHASE1)
- Endogenous Opioid Response to Injections (PHASE4)
- Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder (PHASE1, PHASE2)
- Recovery After Dialysis-Requiring Acute Kidney Injury (NA)
- Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists (PHASE1)
- Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naloxone infusion CI brief — competitive landscape report
- Naloxone infusion updates RSS · CI watch RSS
- Middle Tennessee Research Institute portfolio CI